EVALUATION OF THE EFFICIENCY OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE FOR THE PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ACCORDING TO THE TOTAL NEUROPATHY SCORE
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-1.17257Keywords:
acetylcholinesterase inhibitors, alpha-lipoic acid, chemotherapy, neuropathy, Paclitaxel, Total Neuropathy ScoreAbstract
Aim: To evaluate the efficacy of combination of alpha-lipoic acid and acetylcholinesterase inhibitor (ipidacrine hydrochloride) to prevent the development and improve the course of paclitaxel-induced peripheral neuropathy (PIPN) in patients with breast cancer according to the Total Neuropathy Score. Materials and Methods: 32 patients with breast cancer T1-4N0-3M0 received six cycles of polychemotherapy according to the AT scheme (paclitaxel, doxorubicin) or ET scheme (paclitaxel, epirubicin). Patients were randomized into two groups — without (group I) or with (group II) medication for prevention of neuropathy. A comprehensive neurological examination of patients was performed according to all ten parameters of the Total Neuropathy Score before chemotherapy, and after third and sixth cycles of chemotherapy. Each parameter was evaluated from 0 (no deficit) to 4 (no function/the most severe deficit). The scores obtained from the scale were summarized to obtain a total score from 0 to 40. Results: The use of alpha-lipoic acid in combination with an acetylcholinesterase inhibitor (ipidacrine hydrochloride) significantly reduces the symptoms and severity of PIPN. The manifestations of PIPN in patients of the control group were significantly more severe compared to the group in which the study drugs were used. The average severity of neuropathy after 3 and 6 cycles was 1.75 and 2.62 in group I, and 1.12 and 1.62 — in group II, respectively (improvement by 15.75% (p < 0.05) and 25.00% (p < 0.001) after 3 and 6 cycles). Conclusions: Proposed combination of alpha-lipoic acid and ipidacrine hydrochloride led to a statistically significant reduction in the severity of PIPN, and thus to improvement of the functional capacity and quality of life of patients.
References
Kellokumpu-Lehtinen P, Tuunanen T, Asola R, et al. Weekly paclitaxel-an effective treatment for advanced breast cancer. Anticancer Res 2013; 33: 2623–7.
Kampan NC, Madondo MT, McNally OM, et al. Paclitaxel and its evolving role in the management of ovarian cancer. Biomed Res Int 2015; 2015: 1–21. https://doi.org/10.1155/2015/413076
Kosmidis P, Fountzilas G, Baka S, et al. Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study. Anticancer Res 2007; 27: 4391–5.
Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77: 1561–5. https://doi.org/10.1073/pnas.77.3.1561
Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994; 5: 495–505. https://doi.org/10.1093/oxfordjournals.annonc.a058903
Pasquier E, Honore S, Pourroy B, et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005; 65: 2433–40. https://doi.org/10.1158/0008-5472.CAN-04-2624
Postma TJ, Vermorken JB, Liefting AJ, et al. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489–94. https://doi.org/10.2174/157015906776359568
Forsyth PA, Balmaceda C, Peterson K, et al. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 1997; 35: 47–53. https://doi.org/10.1023/a:1005805907311
Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain 2014; 155: 2461–70. https://doi.org/10.1016/j.pain.2014.09.020
Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13: 27–46. https://doi.org/10.1111/j.1529-8027.2008.00156.x
Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32: 1941–67. https://doi.org/10.1200/JCO.2013.54.0914
Tofthagen C. Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 2010; 14: 22–8. https://doi.org/10.1188/10.CJON.E22-E28
Kuroi K, Shimozuma K. Neurotoxicity of taxanes: symptoms and quality of life assessment. Breast Cancer 2004; 11: 92–9. https://doi.org/10.1007/BF02968010
Miaskowski C, Mastick J, Paul SM, et al. Impact of chemotherapy-induced neurotoxicities on adult cancer survivors’ symptom burden and quality of life. J Cancer Surviv 2018; 12: 234–45. https://doi.org/10.1007/s11764-017-0662-8
Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer 2004; 11: 82–5. https://doi.org/10.1007/BF02968008
Gornstein E, Schwarz TL. The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology 2014; 76: 175–83. https://doi.org/10.1016/j.neuropharm.2013.08.016
Duggett NA, Griffiths LA, McKenna OE, et al. Oxidative stress in the development, maintenance and resolution of paclitaxel-induced painful neuropathy. Neuroscience 2016; 333: 13–26. https://doi.org/10.1016/j.neuroscience.2016.06.050
Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? Neurosci Lett 2015; 596: 90–107. https://doi.org/10.1016/j.neulet.2014.10.014
Ishii N, Tsubouchi H, Miura A, et al. Ghrelin alleviates paclitaxel-induced peripheral neuropathy by reducing oxidative stress and enhancing mitochondrial anti-oxidant functions in mice. Eur J Pharmacol 2018; 819: 35–42. https://doi.org/10.1016/j.ejphar.2017.11.024
Karpińska A, Gromadzka G. Oxidative stress and natural antioxidant mechanisms: the role in neurodegeneration. From molecular mechanisms to therapeutic strategies. Postepy Hig Med Dosw 2013; 67: 43–53 (in Polish). https://doi.org/10.5604/17322693.1029530
Ramanathan B, Jan KY, Chen CH, et al. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 2005; 65: 8455–60. https://doi.org/10.1158/0008-5472.CAN-05-1162
Gedlicka C, Kornek GV, Schmid K, et al. Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol 2003; 14: 339–40. https://doi.org/10.1093/annonc/mdg051
Mrakic-Sposta S, Vezzoli A, Maderna L, et al. R(+)-thioctic acid effects on oxidative stress and peripheral neuropathy in type ii diabetic patients: preliminary results by electron paramagnetic resonance and electroneurography. Oxid Med Cell Longev 2018; 2018: 1767265. https://doi.org/10.1155/2018/1767265
Melli G, Taiana M, Camozzi F, et al. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol 2008; 214: 276–84. https://doi.org/10.1016/j.expneurol.2008.08.013
Agathos E, Tentolouris A, Eleftheriadou I, et al. Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. J Int Med Res 2018; 46: 1779–90. https://doi.org/10.1177/0300060518756540
Jin HY, Lee NY, Ko HA, et al. Comparison of sensory tests and neuronal quantity of peripheral nerves between streptozotocin (STZ)-induced diabetic rats and paclitaxel (PAC)-treated rats. Somatosens Mot Res 2016; 33: 186–95. https://doi.org/10.1080/08990220.2016.1239577
Schloss J, Colosimo M, Vitetta L. New insights into potential prevention and management options for chemotherapy-induced peripheral neuropathy. Asia Pac J Oncol Nurs 2016; 3: 73–85. https://doi.org/10.4103/2347-5625.170977
Takada-Takatori Y, Kume T, Sugimoto M, et al. Acetylcholinesterase inhibitors used in treatment of Alzheimer’s disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 2006; 51: 474–86. https://doi.org/10.1016/j.neuropharm.2006.04.007
Di Cesare Mannelli L, Zanardelli M, Ghelardini C. Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models. Eur J Pharmacol 2013; 711: 87–94. https://doi.org/10.1016/j.ejphar.2013.04.022
Di Cesare Mannelli L, Pacini A, Matera C, et al. Involvement of α7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation. Neuropharmacology 2014; 79: 37–48. https://doi.org/10.1016/j.neuropharm.2013.10.034
Ferrier J, Bayet-Robert M, Dalmann R, et al. Cholinergic neurotransmission in the posterior insular cortex is altered in preclinical models of neuropathic pain: key role of muscarinic M2 receptors in donepezil-induced antinociception. J Neurosci 2015; 35: 16418–30. https://doi.org/10.1523/JNEUROSCI.1537-15.2015
Romero HK, Christensen SB, Di Cesare Mannelli L, et al. Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain. Proc Natl Acad Sci USA 2017; 114: 1825–32. https://doi.org/10.1073/pnas.1621433114
Kyte SL, Toma W, Bagdas D, et al. Nicotine prevents and reverses paclitaxel-induced mechanical allodynia in a mouse model of CIPN. J Pharmacol Exp Ther 2018; 364: 110–9. https://doi.org/10.1124/jpet.117.243972
Toma W, Kyte SL, Bagdas D, et al. The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal. Exp Neurol 2019; 320: 113010. https://doi.org/10.1016/j.expneurol.2019.113010
Kawashiri T, Shimizu S, Shigematsu N, et al. Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect. J Pharmacol Sci 2019; 140: 291–4. https://doi.org/10.1016/j.jphs.2019.05.009
Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology 1999; 53: 1660–4. https://doi.org/10.1212/wnl.53.8.1660
Cavaletti G, Cornblath DR, Merkies ISJ, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 2013; 24: 454–62. https://doi.org/10.1093/annonc/mds329
Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007; 12: 210–5. https://doi.org/10.1111/j.1529-8027.2007.00141.x
Gilchrist LS, Tanner L. The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers. Support Care Cancer 2013; 21: 847–56. https://doi.org/10.1007/s00520-012-1591-8
Liniger C, Albeanu A, Bloise D, et al. The tuning fork revisited. Diabet Med 1990; 7: 859–64. https://doi.org/10.1111/j.1464-5491.1990.tb01319.x
Crausaz FM, Clavel S, Liniger C, et al. Additional factors associated with plantar ulcers in diabetic neuropathy. Diabet Med 1988; 5: 771–5. https://doi.org/10.1111/j.1464-5491.1988.tb01106.x
Bergin PS, Bronstein AM, Murray NM, et al. Body sway and vibration perception thresholds in normal aging and in patients with polyneuropathy. J Neurol Neurosurg Psychiatry 1995; 58: 335–40. https://doi.org/10.1136/jnnp.58.3.335
Whitton TL, Johnson RW, Lovell AT. Use of the Rydel-Seiffer graduated tuning fork in the assessment of vibration threshold in postherpetic neuralgia patients and healthy controls. Eur J Pain 2005; 9: 167–71. https://doi.org/10.1016/j.ejpain.2004.05.001
Kästenbauer T, Sauseng S, Brath H, et al. The value of the Rydel-Seiffer tuning fork as a predictor of diabetic polyneuropathy compared with a neurothesiometer. Diabet Med 2004; 21: 563–7. https://doi.org/10.1111/j.1464-5491.2004.01205.x
Claus D, Carvalho VP, Neundörfer B, et al. Perception of vibration. Normal findings and methodologic aspects. Nervenarzt 1988; 59: 138–42 (in German).
Chaudhry V, Rowinsky EK, Sartorius SE, et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994; 35: 304–11. https://doi.org/10.1002/ana.410350310
Berger T, Malayeri R, Doppelbauer A, et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 1997; 33: 1393–9. https://doi.org/10.1016/s0959-8049(97)00103-2
Cavaletti G, Cavalletti E, Montaguti P, et al. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 1997; 18: 137–45
Allen DT, Kiernan JA. Permeation of proteins from the blood into peripheral nerves and ganglia. Neuroscience 1994; 59: 755–64. https://doi.org/10.1016/0306-4522(94)90192-9
Zajączkowska R, Kocot-Kępska M, Leppert W, et al. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci 2019; 20: 1451. https://doi.org/10.3390/ijms20061451
Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci 2017; 10: 174. https://doi.org/10.3389/fnmol.2017.00174
Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013; 63: 419–37. https://doi.org/10.3322/caac.21204
Stillman M, Cata JP. Management of chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 2006; 10: 279–87. https://doi.org/10.1007/s11916-006-0s033-z
Alberti P, Cavaletti G. Management of side effects in the personalized medicine era: chemotherapy-induced peripheral neuropathy. Methods Mol Biol 2014; 1175: 301–22. https://doi.org/10.1007/978-1-4939-0956-8_12
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
